Xenical Research Today is a free monthly online journal that collates and summarizes the latest research about Xenical, including details on orlistat, side-effects, obesity, weight loss, dieting. | ||||||
|
The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam MH Department of Obstetrics & Gynecology, Sabzevar University of Medical Sciences, Sabzevar, Iran, sedighe_ghandi@yahoo.com. PURPOSE: Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome. METHODS: A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months. RESULTS: There was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and serum lipid. Women in metformin group showed a significant reduction in serum LH. CONCLUSIONS: Both metformin and orlistat showed a similar effect on weight loss and ovulation rates. Published 12 April 2011 in J Assist Reprod Genet. Articles on Xenical published 12 April 2011: The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet. PURPOSE: Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome. METHODS: A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months. RESULTS: There was no significant ... [Abstract] [Full-text] The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet. PURPOSE: Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome. METHODS: A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months. RESULTS: There was no significant ... [Abstract] [Full-text] Articles on Xenical published 7 April 2011: This study evaluated the hypolipidemic and antiobesity effects of phloroacetophenone (2',4',6'-trihydroxyacetophenone, THA) isolated from MYRCIA MULTIFLORA and their relationship with triglyceride (TG) intestinal absorption and pancreatic lipase activity inhibition. The hypolipidemic effect of THA was evaluated by acute (Triton WR-1339 treatment) and chronic assay (high-fat diet treatment), the antiobesity effect was evaluated by chronic assay (high-fat diet treatment), while the inhibition of ... [Abstract] [Full-text] This study evaluated the hypolipidemic and antiobesity effects of phloroacetophenone (2',4',6'-trihydroxyacetophenone, THA) isolated from MYRCIA MULTIFLORA and their relationship with triglyceride (TG) intestinal absorption and pancreatic lipase activity inhibition. The hypolipidemic effect of THA was evaluated by acute (Triton WR-1339 treatment) and chronic assay (high-fat diet treatment), the antiobesity effect was evaluated by chronic assay (high-fat diet treatment), while the inhibition of ... [Abstract] [Full-text] This study evaluated the hypolipidemic and antiobesity effects of phloroacetophenone (2',4',6'-trihydroxyacetophenone, THA) isolated from MYRCIA MULTIFLORA and their relationship with triglyceride (TG) intestinal absorption and pancreatic lipase activity inhibition. The hypolipidemic effect of THA was evaluated by acute (Triton WR-1339 treatment) and chronic assay (high-fat diet treatment), the antiobesity effect was evaluated by chronic assay (high-fat diet treatment), while the inhibition of ... [Abstract] [Full-text] Articles on Xenical published 5 April 2011: Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study. Eur J Cardiovasc Prev Rehabil. Background: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beneficially impact CV medication use. Objective: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug. Design: An historical cohort study in the PHARMO pharmacy registry ... [Abstract] [Full-text] Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study. Eur J Cardiovasc Prev Rehabil. Background: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beneficially impact CV medication use. Objective: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug. Design: An historical cohort study in the PHARMO pharmacy registry ... [Abstract] [Full-text] Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study. Eur J Cardiovasc Prev Rehabil. Background: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beneficially impact CV medication use. Objective: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug. Design: An historical cohort study in the PHARMO pharmacy registry ... [Abstract] [Full-text] © 2004-2011 Xenical Research Today. All Rights Reserved. |
| ||||